OpenLB
Open Library of Bioscience
Advanced Search
Open forum infectious diseases
Jul, 2020;7 (7): ofaa243.

SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020.

Satoshi Kutsuna, Tadaki Suzuki, Kayoko Hayakawa, Shinya Tsuzuki, Yusuke Asai, Tetsuya Suzuki, Satoshi Ide, Keiji Nakamura, Yuki Moriyama, Noriko Kinoshita, Naoto Hosokawa, Ryosuke Osawa, Ryosuke Yamamuro, Yutaro Akiyama, Yusuke Miyazato, Hidetoshi Nomoto, Takato Nakamoto, Masayuki Ota, Sho Saito, Masahiro Ishikane, Shinichiro Morioka, Kei Yamamoto, Mugen Ujiie, Mari Terada, Fukumi Nakamura-Uchiyama, Toshinori Sahara, Masahiro Sano, Akifumi Imamura, Noritaka Sekiya, Kazuaki Fukushima, Akihiko Kawana, Yuji Fujikura, Tomoya Sano, Ryohei Suematsu, Naoya Sakamoto, Kaoru Nagata, Tomoyuki Kato, Harutaka Katano, Takaji Wakita, Haruhito Sugiyama, Norihiro Kokudo, Norio Ohmagari
Author Information
  1. Satoshi Kutsuna: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  2. Tadaki Suzuki: COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
  3. Kayoko Hayakawa: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  4. Shinya Tsuzuki: AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  5. Yusuke Asai: AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  6. Tetsuya Suzuki: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  7. Satoshi Ide: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  8. Keiji Nakamura: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  9. Yuki Moriyama: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  10. Noriko Kinoshita: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  11. Naoto Hosokawa: Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan.
  12. Ryosuke Osawa: Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan.
  13. Ryosuke Yamamuro: Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan.
  14. Yutaro Akiyama: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  15. Yusuke Miyazato: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  16. Hidetoshi Nomoto: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  17. Takato Nakamoto: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  18. Masayuki Ota: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  19. Sho Saito: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  20. Masahiro Ishikane: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  21. Shinichiro Morioka: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  22. Kei Yamamoto: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  23. Mugen Ujiie: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  24. Mari Terada: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  25. Fukumi Nakamura-Uchiyama: Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan.
  26. Toshinori Sahara: Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan.
  27. Masahiro Sano: Department of Infectious Diseases, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Itabashi-ku, Tokyo, Japan.
  28. Akifumi Imamura: Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
  29. Noritaka Sekiya: Department of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
  30. Kazuaki Fukushima: Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan.
  31. Akihiko Kawana: Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan.
  32. Yuji Fujikura: Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan.
  33. Tomoya Sano: Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan.
  34. Ryohei Suematsu: Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan.
  35. Naoya Sakamoto: Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Sumida-ku, Tokyo, Japan.
  36. Kaoru Nagata: Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan.
  37. Tomoyuki Kato: Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan.
  38. Harutaka Katano: COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
  39. Takaji Wakita: COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan.
  40. Haruhito Sugiyama: National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  41. Norihiro Kokudo: National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan.
  42. Norio Ohmagari: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan. ORCID
PMID: 32754627 DOI: 10.1093/ofid/ofaa243

Abstract

BACKGROUND: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) was found to be the causative microorganism of coronavirus disease 2019 (COVID-19), which started to spread in Wuhan, China. This study was to evaluate the effectiveness of questionnaire, symptoms-based screening, and polymerase chain reaction (PCR) screening of returnees from COVID-19-endemic areas on a chartered flight, to examine the proportion of infected persons and the proportion of asymptomatic persons among infected persons who returned from Wuhan.
METHODS: A retrospective cohort study was done in 7 tertiary medical institutions in Japan. A total of 566 Japanese who returned from Wuhan participated in the study.
RESULTS: Overall, 11 of the 566 passengers had a positive SARS-CoV-2 PCR result for pharyngeal swabs and 6 were asymptomatic. Only fever differed between SARS-CoV-2-positive and -negative individuals ( < .043). Six of the 11 PCR-positive individuals were asymptomatic; 4 remained positive on day 10, and 1 asymptomatic person tested positive up to day 27. Two of the 11 were negative on the first PCR test and positive on the second.
CONCLUSIONS: Our results will be important insights on screening returnees from locked-down cities, as well as providing important data on the proportion of asymptomatic individuals infected with SARS-CoV-2. A 13-day observation period and a second round of PCR may be effective to screen patients, including asymptomatic infections.

Keywords

COVID-19 SARS-CoV-2 Wuhan lockdown returnees

References

  1. Nature. 2020 Mar;579(7798):270-273 [PMID: 32015507]
  2. Lancet. 2020 Feb 22;395(10224):565-574 [PMID: 32007145]
  3. N Engl J Med. 2020 Mar 26;382(13):1199-1207 [PMID: 31995857]
  4. Emerg Infect Dis. 2005 Jul;11(7):1142-5 [PMID: 16022801]
  5. N Engl J Med. 2020 Feb 27;382(9):872-874 [PMID: 31991079]
  6. Clin Infect Dis. 2017 Mar 15;64(6):736-742 [PMID: 28011603]
  7. J Infect Dis. 2020 May 11;221(11):1757-1761 [PMID: 32067043]
  8. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  9. MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246 [PMID: 32134909]
  10. Lancet. 2020 Feb 15;395(10223):507-513 [PMID: 32007143]
  11. Euro Surveill. 2020 Feb;25(5): [PMID: 32046816]
  12. N Engl J Med. 2020 Mar 5;382(10):970-971 [PMID: 32003551]
  13. Travel Med Infect Dis. 2019 Jan - Feb;27:27-32 [PMID: 30550839]
  14. N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
  15. Int J Infect Dis. 2020 Apr;93:284-286 [PMID: 32145466]
  16. Lancet. 2020 Feb 29;395(10225):689-697 [PMID: 32014114]
  17. N Engl J Med. 2020 Mar 19;382(12):1177-1179 [PMID: 32074444]
  18. JAMA. 2020 Feb 7;: [PMID: 32031570]
  19. N Engl J Med. 2020 Mar 26;382(13):1278-1280 [PMID: 32069388]
  20. JAMA. 2020 Feb 21;: [PMID: 32083643]
Journal Article
Article has an altmetric score of 97

Word Cloud

Created with Highcharts 10.0.0asymptomaticSARS-CoV-2WuhanPCRpositivestudyscreeningreturneesproportioninfectedpersons11individualscoronavirusCOVID-19Chinareturned566JapanesedaysecondimportantBACKGROUND:Severeacuterespiratorysyndrome-related2foundcausativemicroorganismdisease2019startedspreadevaluateeffectivenessquestionnairesymptoms-basedpolymerasechainreactionCOVID-19-endemicareascharteredflightexamineamongMETHODS:retrospectivecohortdone7tertiarymedicalinstitutionsJapantotalparticipatedRESULTS:Overallpassengersresultpharyngealswabs6feverdifferedSARS-CoV-2-positive-negative<043SixPCR-positive4remained101persontested27TwonegativefirsttestCONCLUSIONS:resultswillinsightslocked-downcitieswellprovidingdata13-dayobservationperiodroundmayeffectivescreenpatientsincludinginfectionsScreeningTestReturneesJanuary2020lockdown

Similar Articles

Cited By